Background
Histone acetylation
HAT
HAT Families | Family members | HAT domain motifsa | Function domainsb | HAT reaction mechanismc |
---|---|---|---|---|
GNAT | Gcn5 | C-D-A-B | AT domains bromodomains | kinetic mechanism |
PCAF | ||||
Elp3 | ||||
Hat1 | ||||
Hpa2 | ||||
Nut1 | ||||
MYST | MOZ | A | AT domains | ping-pong catalytic mechanism |
Ybf2 (Sas3) | plant homeo domains | |||
Sas2 | zinc finger domains | |||
Tip60 | chromodomains | |||
p300/CBP | p300 | E-D-A-B | zinc finger region | Theorell–Chance mechanism |
(cys, ZZ and TAZ domain) | ||||
CBP | HAT domains | |||
Bromodomains |
HDAC
Class of HDAC | members of each class | homology to yeast | location | HDACs as anticancer targets |
---|---|---|---|---|
class I | HDACS 1, 2, 3 and 8 | RPD3 protein | in the nucleus | i) DNA-based process (DNA repair, replication and recombination) ; ii) cell-cycle progression (cell proliferation, differentiation, apoptosis) ; iii) migration; iiii) immunity. (See below for more details) |
class IIa | HDACs 4, 5, 7 and 9 | Hda1 protein | shuttle between the nucleus and the cytoplasm | |
class IIb | HDACs 6 and 10 | |||
class IV | HDAC11 | mixed homology between Rpd-3 and Hda1 | in the nucleus | |
class III | (NAD+-dependent) SIRT1, 2, 3, 4, 5, 6 and 7 | Sir2 protein | in the nucleus |
Acetylation and gene expression
HDACs and HDACis in cancer
HDACs in cancer
HDACis
pathway | genes/signalings | tumours affected | representative drug |
---|---|---|---|
apoptosis | TNBC and pancreatic cancer | SAHA, NaB , VPA and TSA | |
proapoptotic proteins of Bcl-2 family, such as Bim, Bmf, Bax, Bak and Bik ↑ antiapoptotic proteins of Bcl-2 family, such as Bcl-2, Bcl-XL, Bcl-w and Mcl-1 ↓ [93] | melanoma | SBHA | |
Mesothelioma and leukemia | LBH589 and LAQ824 | ||
TBP2 ↑-Trx ↓-ASK1 signaling ↑ [100] | prostate cancer | SAHA | |
ROS ↑ [101] | CLL | MS-275 | |
TRAIL-DR5 ↑ FASL-FAS (Apo-1 or CD95) ↑ | leukaemia, breast cancer | VPA, SAHA and TSA | |
human RAD23 homolog B (HR23B) ↑ [104] | U2OS cells | SAHA | |
breast cancer | TSA and LAQ824 | ||
cell death | NF-κβ ↑ [107] AKT-mTOR signaling ↓ [94] | Prostate Cancer glioblastoma | SAHA SAHA |
cell arrest | CML-BC cells, colon cancer and bladder carcinoma | LAQ824, SAHA and Butyrate | |
p27 ↑ [111] | leukemia and breast cancer | SAHA and TSA | |
GADD45 α and GADD45 β ↑ [112] | colon carcinoma | TSA and Butyrate | |
TGF-βRII ↑ - c-MYC ↓ [113] | Ewing's sarcoma (EWS) and neuroblastoma | MS-275 | |
angiogenesis | HIF-1a ↓ [114] VEGF ↓ [115] | Lewis lung carcinoma HepG2 cell | FK228 TSA |
DNA repair | Ku86 ↓ Ku70 ↓ [116] | melanoma cells | sodium butyrate (NaB) |
RAD51 ↓ BRCA1&2 ↓ [117] | human squamous carcinoma cells (SQ-20B) | TSA | |
immunity | MHC class I genes ↑ tumor antigens ↑ PD-1 ligands ↑ [118] | melanoma | LBH589, MS-275 and MGCD0103 |
Treg cells ↓ [119] | renal and prostate cancer | entinostat |
HDACis in clinic
target | chemical classes | compounds | source | Isotype selectivity | study phase | reference |
---|---|---|---|---|---|---|
Pan-HDAC | Hydroxamic acid | Vorinostat (SAHA) | Synthetic | class I, II and IV | FDA approval (CTCL) | [121] |
Belinostat(PXD-101) | Synthetic | class I and II | FDA approval (PTCL) | [15] | ||
Panobinostat (LBH-589) | Synthetic | class I, II and IV | FDA approval (PTCL and multiple myelomas) | [122] | ||
Trichostatin A (TSA) | Natural | class I and II | Phase I (Relapsed or Refractory hematologic malignancies ) | NCT03838926 | ||
Quisinostat (JNJ-16241199) | Synthetic | class I and II | phase II (CTCL) | NCT01486277 | ||
WW437 | Synthetic | HDAC 2 and 4 | pre-clinical | [123] | ||
short chain fatty acids | Pivaloyloxmethyl butyrate (AN-9) | Synthetic | class I and IIa | phase II (melanoma) phase I (CLL) | NCT00087477 NCT00083473 | |
Sodium Butyrate (NaB) | Natural | class I and IIa | phase I (Colorectal cancer ) | [124] | ||
Sodium Phenylbutyrate (4-PB) | Synthetic | class I and IIa | FDA approval (urea cycle disorders) | [10] | ||
Valproate (valproic acid) | Synthetic | class I and IIa | phase I (Brain and Central Nervous System Tumors) | [125] | ||
Benzamides | Entinostat (MS-275) | Synthetic | class I | phase II (Hodgkin's Lymphoma) | [126] | |
Tacedinaline (CI-994) | Synthetic | class I | phase II (Myeloma) | NCT00005624 | ||
Mocetinostat (MG-0103) | Synthetic | class I and IV | phase I (Hodgkin's Lymphoma) | [127] | ||
Cyclic peptides | Romidepsin (depsipeptide, FK228) | Natural | class I | FDA approval (CTCL) | [128] | |
electrophilic ketones | trapoxins(TPX) | Natural | class I | NA | [129] | |
a-ketoamides | Synthetic | NA | NA | [130] | ||
heterocyclic ketones | Synthetic | NA | NA | [131] | ||
miscellaneous compounds | Diallyl Trisulfide (DATS) | Natural | NA | pre-clinical (glioblastoma) | [132] | |
sirtuin inhibitors | cambinol | Synthetic | SIRT1 and 2 | pre-clinical | [133] | |
EX-527 | Synthetic | SIRT1 and 2 | pre-clinical | |||
sirtinol | Synthetic | SIRT1 and 2 | pre-clinical | |||
nicotinamide | Synthetic | class III | phase III (laryngeal cancer) | |||
specific HDAC | Hydroxamate Derivatives | Azelaic Bishydroxamic Acid (ABHA) | Synthetic | HDAC 3 | NA | [134] |
CBHA (m-carboxycinnamic acid bis-hydroxamide) | Synthetic | HDAC 3 | pre-clinical | [135] | ||
NA | I-7ab | Synthetic | HDAC 3 | NA | [136] | |
RGFP966 | Synthetic | HDAC 3 | pre-clinical (CTCL) | [137] | ||
PCI34051 | Synthetic | HDAC 8 | pre-clinical (T-cell lymphomas or leukemias) | [138] | ||
C149 | Synthetic | HDAC 8 | pre-clinical (T-cell lymphoma and neuroblastoma) | [139] | ||
Benzamides | Ricolinosta(ACY-1215) | Synthetic | HDAC 6 | phase II (relapsed/refractory lymphoid malignancies ) | NCT02091063 | |
tubacin | Synthetic | HDAC 6 | pre-clinical (ALL) | [140] | ||
Polyketides | Depudecin | Natural | HDAC 1 | NA | [71] | |
sirtuin inhibitors | SEN196 | Synthetic | SIRT1 | NA | [141] | |
COMPOUND 6J | Synthetic | SIRT2 | NA | [142] | ||
JGB1741 | Synthetic | SIRT1 | NA | [143] | ||
bromodomain | BET inhibitors | JQ1 | Synthetic | BRD4 | pre-clinical (CAA) | [144] |
I-BET | Synthetic | BET | pre-clinica (Breast and lung cancer) | [145] | ||
BY27 | Synthetic | BD2 | NA | [146] | ||
hybrid molecules | chimeric | CUDC907 | Synthetic | HDAC /PI3K | phase II (Thyroid Cancer) | NCT03002623 |
CUDC101 | Synthetic | EGFR/Her-2/HDAC 1 | Phase I (head and neck, gastric, breast, liver, and non-small cell lung cancer) | NCT01171924 |
HDACis in GBM
HDACis monotherapy
Mechanisms of HDACis in GBM
alterations | affected part | agents |
---|---|---|
p21Waf1/Cip1, p27↑ | cell cycle arrest | |
DR5, TNFα, p53, Bad, Bax, Bim, chop, Puma, m-calpian↑ | proapoptotic genes | |
vasculogenic mimicry, VEGF, EGFR↓ | angiogenesis | |
Bcl2, Bcl-XL↓ | antiapoptotic genes | |
EZH2, MMP-2↓ | invasion | |
p-PTEN/p-AKT, pFAK/p-STAT3↓ | pathways | |
CDK2, CDK4, CDK6, cyclins D1, cyclins D2↓ | progrowth genes | |
caspase 8, caspase 9, caspase 3 | apoptotic cascade activation | |
HOTAIR↓ | tumor promoting lncRNA | I-BET151 [183] |
Ras, c-myc↓ | oncogenes | |
CD133, Bmi1↓ | GSCs markers | SAHA [182] |
Single HDACis in GBM
HDACis-involved combination therapy
Sensitization | HDACis | synergistic members | reference |
---|---|---|---|
chemotherapy | FK228 | Temozolomide | [187] |
MS275 | Temozolomide, etoposide, and cisplatin | [188] | |
trichostatin A | lomustine | [189] | |
HDAC2 inhibitor | Temozolomide | [190] | |
RGFP109 | Temozolomide | [191] | |
Tubastatin A | Temozolomide | ||
Radiotherapy | PCI-24781 | Radiation | [194] |
Tinostamustine(EDO-S101) | Radiation | [195] | |
trichostatin A | Radiation | [196] | |
immunotherapy | J22352 | PD-L1 | [197] |
demethylase | vorinostat or PCI-24781 | LSD1 | [198] |
panobinostat | DZ-Nep | [199] | |
BRD inhibition | panobinostat | JQ1 or OTX015 | |
RTKi | 4-PB | gefitinib or vandetanib | [202] |
MS275, scriptaid, SAHA, TSA | Erlotinib | [203] | |
topoisomerase inhibitor | SAHA | SN38 | [204] |
virotherapy | trichostatin A | dl520 | [205] |
Scriptaid, LBH589 | Delta24-RGD | [206] | |
others | valproic acid (VPA) | Fluvastatin | [207] |
sodium butyrate (NaB) | quercetin | [208] | |
tubastatin A | celecoxib | [209] | |
panobinostat | BEZ235 | [210] | |
vorinostat | tranylcypromine | [211] | |
SAHA | olaparib | [212] |
HDACis | synergistic members | conditions | phase | trial identifier | reference |
---|---|---|---|---|---|
Vorinostat (SAHA) | Bevacizumab | Recurrent GBM | phase II | NCT01738646 | [213] |
Bevacizumab, Temozolomide | Recurrent Malignant Gliomas | phase I/II | NCT00939991 | [214] | |
Temozolomide | Malignant Gliomas | phase I | NCT00268385 | [215] | |
Radiation | Recurrent Glioma | phase I | NCT01378481 | - | |
Isotretinoin, Temozolomide | Recurrent GBM | phase I/II | NCT00555399 | - | |
Erlotinib, Temozolomide | Recurrent GBM | phase I/II | NCT01110876 | - | |
Temozolomide, Radiation | Newly Diagnosed GBM | phase I/II | NCT00731731 | [216] | |
Pembrolizumab, Temozolomide | Newly Diagnosed GBM | phase I | NCT03426891 | - | |
Bortezomib | Recurrent GBM | phase II | NCT00641706 | [217] | |
Bevacizumab, Irinotecan | Recurrent GBM | phase I | NCT00762255 | [218] | |
Panobinostat (LBH-589) | Bevacizumab | Recurrent High Grade Glioma | phase I/II | NCT00859222 | [219] |
Radiation | Recurrent Glioma | phase I | NCT01324635 | - | |
Valproate (valproic acid, VPA) | Sorafenib Tosylate, Sildenafil Citrate | Recurrent High-Grade Glioma | phase II | NCT01817751 | - |
Temozolomide, Radiation | High Grade Gliomas | phase II | NCT00302159 | ||
Nivolumab, Radiation | Recurrent GBM | phase I | NCT02648633 | - | |
Belinostat (PXD101) | Temozolomide, Radiation | GBM | phase II | NCT02137759 | - |